These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Transperineal ultrasound-guided radioactive seed implantation for organ-confined carcinoma of the prostate.
    Author: Stokes SH, Real JD, Adams PW, Clements JC, Wuertzer S, Kan W.
    Journal: Int J Radiat Oncol Biol Phys; 1997 Jan 15; 37(2):337-41. PubMed ID: 9069305.
    Abstract:
    PURPOSE: This retrospective study was undertaken to: (a) determine the prognostic significance of pretreatment and 1-year nadir serum prostate specific antigen (PSA) levels in organ-confined carcinoma of the prostate treated with ultrasound-guided radioactive 125I seed implantation; (b) determine the factors associated with postimplant morbidity and whether modification of the technique would reduce morbidity; (c) evaluate the local control rate and disease-free survival of patients undergoing seed implantation. METHODS AND MATERIALS: From October 1988 through December 1992, 142 patients with organ-confined adenocarcinoma of the prostate and a Gleason score < or = 7 underwent ultrasound-guided radioactive 125I seed implantation as an alternative to radical prostatectomy. Patients were considered to have persistent or progressive disease if there was evidence of local progression on digital exam, or if there were two consecutive increases in the PSA level. Patients suspected of persistent or progressive disease underwent restaging to include CT scan of the pelvis, bone scan, and ultrasound-guided prostate biopsy. Patients with increasing PSA levels in which active disease could not be confirmed were considered biochemical failures with occult systemic disease and were offered hormone ablation. RESULTS: With 1-6-year follow-up, median 30 months, the relapse patterns were prostate 4 (2.8%), bone 4 (2.8%), rising PSA 16 (11%). Pretreatment PSA level correlated with subsequent recurrence; pretreatment PSA < or = 4 (0), 4.1 to 10 (14%), 10.1 to 20 (21%), 20.1 to 50 (58%). Disease free survival at 2 years was 90% and at 5 years 76%. Nadir PSA (nPSA) at 1 year also correlated with recurrence: nPSA < or = 1 (3%), nPSA 1 < or = 4 (50%), and nPSA > or = 4 (100%). Seed implantation was well tolerated with 31% of patients experiencing RTOG morbidity > or = Grade 2, which typically consisted of transient radiation urethritis, which resolved with conservative measures. Eleven (8%) experienced RTOG morbidity > or = Grade 3. There was no correlation between number of seeds or total millicuries implanted and subsequent morbidity. However, reduction in the periurethral seed intensity reduced > or = Grade 3 morbidity from 11 to 4%. CONCLUSION: Ultrasound-guided radioactive seed implantation provides excellent local control of 97%, with a median 30 month follow-up. Morbidity is comparable to other curative modalities and by modifying Blasko's technique to reduce radioactive seed strength in the periurethral area, significant morbidity is rare. Pretreatment PSA and the nadir PSA at 1 year are important predictors of subsequent disease outcome. With a liberal definition of systemic recurrence as two consecutive increases in PSA levels, the 5-year disease-free survival is 76%.
    [Abstract] [Full Text] [Related] [New Search]